If you have been reading about BPC-157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
== Trial and imprisonment == Allitt had attacked 13 children, four fatally, over a 59-day period. It was only following the death of Becky Phillips that medical staff became suspicious of the number of cardiac arrests on the children's ward and police were called in. It was found that Allitt was the only nurse on duty for all the attacks on the children and had access to the drugs used. Four of Allitt's victims had died. She was charged with four counts of murder, eleven counts of attempted murder, and eleven counts of causing grievous bodily harm. Allitt entered pleas of not guilty to all charges. On 28 May 1993, she was found guilty on each charge and sentenced to 13 concurrent terms of life imprisonment, which she is serving at Rampton Secure Hospital in Nottinghamshire. On 6 December 2007, Mr Justice Stanley Burnton, sitting in the High Court of Justice, London, ordered Allitt to serve the original minimum sentence of 30 years. It was reported that some families of Allitt's victims had previously mistakenly believed that her minimum tariff had been set at 40 years. Her minimum tariff expired in November 2021 and she is now eligible for release on parole. Allitt's motives have never been fully explained. According to one theory, she showed symptoms of a factitious disorder also known as Munchausen syndrome by proxy. On 3 October 2023, it was reported that Allitt was appearing before a mental health tribunal to be assessed for a potential transfer to a mainstream prison. If the transfer takes place, Allitt will be eligible for parole after six months.
A number of structural disorders associated with point mutations of this gene have been described that cause malfunctioning of the heart, such as Type 1R dilated cardiomyopathy and Type 11 hypertrophic cardiomyopathy. Certain defects of the atrial septum have been described recently that could also be related to these mutations. Two cases of dilated cardiomyopathy have been studied involving a substitution of highly conserved amino acids belonging to the protein domains that bind and intersperse with the Z discs. This has led to the theory that the dilation is produced by a defect in the transmission of contractile force in the myocytes. The mutations in ACTC1 are responsible for at least 5% of hypertrophic cardiomyopathies. The existence of a number of point mutations have also been found:
== Role in hunger circuitry == According to Mark L. Andermann and Bradford B. Lowell: "...AgRP neurons and the wiring diagram within which they operate can be viewed as the physical embodiment of the intervening variable, hunger." Stimulation of neurons expressing AgRP can induce robust feeding behavior in mice that will trigger: increased food consumption, increased willingness to work for food, and increased investigation of food odors. Despite this, AgRP neurons are rapidly inhibited upon food presentation and the onset of eating. One mechanism which may account for this discrepancy is the fact that AgRP neurons signal with Neuropeptide Y in order to allow for sustained feeding behavior that outlasts the activation of the neurons. AgRP neurons are also sensitive to satiety and hunger hormonal signals. One is an appetite stimulant, ghrelin which makes AgRP neurons more excitable through interactions with specialized ghrelin receptors. Another is a satiety signal, leptin, which modulates AgRP activity through inwardly rectifying potassium channels, which alter the excitability of the neurons. Leptin can also decrease the ability of AgRP neurons to carry out other physiological functions, such as triggering Long Term Potentiation of adjacent neurons. Although AgRP neurons can drive many different phases of feeding behavior, separate AgRP neurons project to different areas of the brain, demonstrating a parallel organizational structure.
Sources: en.wikipedia.org
Expense must also be duly considered with such assays as they become more frequently applied in very large studies (e.g. potentially involving thousands of samples). While other approaches are also being made commercially available (e.g. iterative mapping of peptides, fluorescent variation of Edman degradation, and nanopores) these (i) remain broadly untested outside the firms involved; (ii) yield largely, if not completely, only proteogenomic data; (iii) are thus, currently at least, quite limited in terms of any capacity for a broad assessment of proteoforms; (iv) are dependent on the quality of the affinity or other (multiple) reagents required which; (v) tends to also increase costs per assay to the consumer. Notably, while promising, nanopore sequencing is (i) still quite early in development; and (ii) remains unproven in terms of throughput and capacity to address the full range of known PTM and adducts. Thus, the capacity for nanopores to quantitatively address the full breadth of a proteome remains untested. Other technical issues such as potential clogging of pores will also need to be addressed with hopefully routine solutions.
The amorphous regions contribute elasticity and the crystalline regions contribute strength and rigidity. More complex polymers such as proteins, with various interacting chemical groups attached to their backbones, self-assemble into well-defined structures. But segments of proteins, and polypeptides that lack secondary structure, are often assumed to exhibit a random-coil conformation in which the only fixed relationship is the joining of adjacent amino acid residues by a peptide bond. This is not actually the case, since the ensemble will be energy weighted due to interactions between amino acid side-chains, with lower-energy conformations being present more frequently. In addition, even arbitrary sequences of amino acids tend to exhibit some hydrogen bonding and secondary structure. For this reason, the term "statistical coil" is occasionally preferred. The conformational entropy of the random-coil stabilizes the unfolded protein state and represents main free energy contribution that opposes to protein folding.
For a compound to reach a tissue, it usually must be taken into the bloodstream – often via mucous surfaces like the digestive tract (intestinal absorption) – before being taken up by the target cells. Factors such as poor compound solubility, gastric emptying time, intestinal transit time, chemical instability in the stomach, and inability to permeate the intestinal wall can all reduce the extent to which a drug is absorbed after oral administration. Absorption critically determines the compound's bioavailability. Drugs that absorb poorly when taken orally must be administered in some less desirable way, like intravenously or by inhalation (e.g. zanamivir). Routes of administration are an important consideration.
Sources: en.wikipedia.org
On 5 October 1959, Trieste departed San Diego for Guam aboard the freighter Santa Maria to participate in Project Nekton, a series of very deep dives in the Mariana Trench. On 23 January 1960, Trieste reached the ocean floor in the Challenger Deep (the deepest southern part of the Mariana Trench), carrying Jacques Piccard (son of Auguste) and Lieutenant Don Walsh, USN. This was the first time a vessel, crewed or uncrewed, had reached the deepest point in the Earth's oceans. The onboard systems indicated a depth of 11,521 metres (37,799 ft), although this was later revised to 10,916 metres (35,814 ft) and more accurate measurements made in 1995 have found the Challenger Deep slightly shallower, at 10,911 metres (35,797 ft). Building a pressure hull is difficult, as it must withstand pressures at its required diving depth. When the hull is perfectly round in cross-section, the pressure is evenly distributed, and causes only hull compression. If the shape is not perfect, the hull deflects more in some places and buckling instability is the usual failure mode. Inevitable minor deviations are resisted by stiffener rings, but even a one-inch (25 mm) deviation from roundness results in over 30 percent decrease of maximal hydrostatic load and consequently dive depth. The hull must therefore be constructed with high precision. All hull parts must be welded without defects, and all joints are checked multiple times with different methods, contributing to the high cost of modern submarines.
The isotope 231Pa can be prepared by irradiating 230Th with slow neutrons, converting it to the beta-decaying 231Th; or, by irradiating 232Th with fast neutrons, generating (as one product) 231Th and 2 neutrons. Protactinium metal has been prepared by reduction of its fluoride with calcium, lithium, or barium at a temperature of 1300–1400 °C.
=== Metabolic === One of the primary areas of interest regarding adropin is its role in metabolic regulation. Research indicates that adropin may play a crucial role in glucose and lipid metabolism. It has been associated with insulin sensitivity, suggesting a potential role in the regulation of blood sugar levels. In animal studies, alterations in adropin levels have been linked to changes in energy expenditure and body weight. For example, some studies have shown that mice with elevated adropin levels tend to be more resistant to diet-induced obesity. A study in humans demonstrated that changes in vascular insulin resistance following short-term adverse lifestyle changes were associated with a decrease in plasma adropin in men but not women, perhaps related to adropin's regulation by estrogen.
=== Eruption of the fighting === 27 December 1918: The uprising starts in the evening with shooting in front of Poznań's police headquarters. Fighting also start in other towns: Szamotuły, Środa Wielkopolska, Pniewy, Opalenica, Buk, Trzemeszno, Września and Gniezno are captured. Poles in Poznań capture the main train station, the main post office and part of city fortifications. 28 December 1918: The Poles in Poznań capture Cytadela (a main stronghold), Fort Grolmann and an armory on ul. Wielkie Garbary The commission of the NRL promotes Captain Stanisław Taczak to temporary commander-in-chief of the uprising (he is also promoted to rank of major). 29 December 1918: The Poles capture Grodzisk Wielkopolski, Kłecko, Kórnik, Wielichowo, Gostyń, Witkowo and other towns. 30 December 1918 Failure of peace talks between the insurgents and the German authorities, the latter refusing to take the responsibility for the hostilities of 27 December. In Poznań, the Poles force the German 6th Regiment of Grenadiers from their barracks. After talks, the regiment leaves the city with their weapons. The Poles capture Wronki, Wągrowiec, Gołańcz. Polish soldiers stop a German offensive against Gniezno near Zdziechowa. 31 December 1918 The Poles capture Kościan, Oborniki Wielkopolskie, Ostrów Wielkopolski. A unit of Poles under command of Paweł Cyms begins offensive on Cuiavia. 1 January 1919 Paderewski leaves Poznań. The capture of Jarocin, Krotoszyn and Mogilno.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.